Open AccessA novel expressed prostatic secretion (EPS)-urine metabolomic signature for the diagnosis of clinically significant prostate cancer
Author(s) -
Denise Drago,
Annapaola Andolfo,
Ettore Mosca,
Alessandro Orro,
Luigi Nocera,
Vito Cucchiara,
Matteo Bellone,
Francesco Montorsi,
Alberto Briganti
Publication year - 2021
Publication title -
cancer biology and medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.517
H-Index - 42
ISSN - 2095-3941
DOI - 10.20892/j.issn.2095-3941.2020.0617
Subject(s) - metabolomics , prostate cancer , medicine , prostate , urine , biomarker discovery , hyperplasia , biomarker , biopsy , magnetic resonance imaging , cancer , urology , bioinformatics , radiology , proteomics , chemistry , biology , biochemistry , gene
Significant efforts are currently being made to identify novel biomarkers for the diagnosis and risk stratification of prostate cancer (PCa). Metabolomics can be a very useful approach in biomarker discovery because metabolites are an important read-out of the disease when characterized in biological samples. We aimed to determine a metabolomic signature which can accurately distinguish men with clinically significant PCa from those affected by benign prostatic hyperplasia (BPH).